Cargando…
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved
Following their successful implementation for the treatment of metastatic breast cancer, the ‘third-generation’ aromatase inhibitors (anastrozole, letrozole, and exemestane) have now become standard adjuvant endocrine treatment for postmenopausal estrogen receptor-positive breast cancers. These drug...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Society for Endocrinology
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689263/ https://www.ncbi.nlm.nih.gov/pubmed/23625614 http://dx.doi.org/10.1530/ERC-13-0099 |